ENTRADA THERAPEUTICS, INC. |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 15.32 USD | +0.13% |
|
-2.14% | -0.20% |
Financials (USD)
| Sales 2024 * | 143M | Sales 2025 * | 33.68M | Capitalization | 486M |
|---|---|---|---|---|---|
| Net income 2024 * | -20M | Net income 2025 * | -147M | EV / Sales 2024 * | 2.68 x |
| Net cash position 2024 * | 104M | Net cash position 2025 * | 141M | EV / Sales 2025 * | 10.2 x |
| P/E ratio 2024 * |
-31
x | P/E ratio 2025 * |
-4.04
x | Employees | 160 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 83.37% |
More Fundamentals
* Assessed data
More news
Latest transcript on Entrada Therapeutics, Inc.
More recommendations
More press releases
| 1 day | +0.13% | ||
| 1 week | -2.14% | ||
| Current month | -2.65% | ||
| 1 month | +11.56% | ||
| 3 months | +22.64% | ||
| 6 months | +7.19% | ||
| Current year | -0.20% |
1 week
14.89
16.08
1 month
13.2616.45
Current year
11.3517.26
1 year
10.7518.44
3 years
5.1236.85
5 years
5.1236.85
10 years
5.1236.85
| Managers | Title | Age | Since |
|---|---|---|---|
Dipal Doshi
CEO | Chief Executive Officer | 48 | 17-07-31 |
Kory Wentworth
DFI | Director of Finance/CFO | 45 | 20-10-31 |
Nathan Dowden
PSD | President | 54 | 19-11-03 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Peter Kim
BRD | Director/Board Member | 65 | 20-11-30 |
Mary Thistle
BRD | Director/Board Member | 64 | 21-05-03 |
Gina Chapman
BRD | Director/Board Member | 57 | 23-08-31 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.00% | 34 M€ | +4.49% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-06-05 | 15.04 | -1.70% | 1 804 |
| 24-06-04 | 15.3 | -2.55% | 94,386 |
| 24-06-03 | 15.7 | +1.49% | 93,037 |
| 24-05-31 | 15.47 | -1.02% | 87,480 |
| 24-05-30 | 15.63 | +1.56% | 62,774 |
Delayed Quote Nasdaq, June 05, 2024 at 10:07 am EDT
More quotes
Entrada Therapeutics, Inc. is a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a class of medicines, which engages intracellular targets that have long been considered inaccessible. The Companyâs Endosomal Escape Vehicle (EEV)-therapeutics are designed to enable the efficient delivery of a range of therapeutics into a variety of organs and tissues, resulting in an improved therapeutic index. Through its proprietary, highly versatile and modular EEV platform (EEV Platform), the Company is building a robust development portfolio of therapeutic candidates. Its first two drug candidates, ENTR-601-44 and VX-670, are in clinical trials. VX-670 for dystrophy type 1 (DM1) is designed to block the triplet repeats in the messenger RNA (mRNA). ENTR-601-44 is in a Phase I clinical trial. The Company also announced the selection of additional clinical candidates within its Duchenne franchise, ENTR-601-45 and ENTR-601-50.
Calendar
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
15.3
USD
Average target price
22.86
USD
Spread / Average Target
+49.43%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -0.20% | 486M | |
| +16.85% | 123B | |
| +13.06% | 107B | |
| -6.22% | 24.01B | |
| +1.51% | 22.59B | |
| -10.09% | 18.16B | |
| -40.52% | 16.84B | |
| -12.31% | 16.23B | |
| +1.73% | 13.43B | |
| +22.24% | 11.32B |
- Stock Market
- Equities
- TRDA Stock
